Recombinant protein COVID 19 vaccine - West China Hospital Sichuan University/WestVac Biopharma
Alternative Names: Coviccine; Recombinant COVID-19 vaccine (Sf9 cells); Recombinant SARS-CoV-2 vaccine (Sf9 Cells)Latest Information Update: 08 May 2024
At a glance
- Originator West China Hospital Sichuan University
- Developer West China Hospital Sichuan University; Westvac Biopharma
- Class COVID-19 vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered COVID 2019 infections
Most Recent Events
- 30 Dec 2023 WestVac Biopharma completes a clinical trial for COVID-2019 infections (In volunteers) in China (IM) (NCT05465785)
- 22 Feb 2023 Westvac Biopharma receives clinical trial approval from the NMPA for phase I/II trial
- 22 Feb 2023 WestVac Biopharma plans a phase I/II trial in COVID-2019 infections (Prevention, In children, In adolescents) in China in March 2022 (NCT05013983)